Abstract

Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required for most HIV broadly neutralizing antibodies (bnAbs) are major impediments to the development of an effective HIV vaccine. Rational protein vaccine design and non-conventional immunization strategies are potential avenues to overcome these hurdles. Here, we report using implantable osmotic pumps to continuously deliver a series of epitope-targeted immunogens to rhesus macaques over the course of six months to prime and elicit antibody responses against the conserved fusion peptide (FP). GC responses and antibody specificities were tracked longitudinally using lymph node fine-needle aspirates and electron microscopy polyclonal epitope mapping (EMPEM), respectively, to show antibody responses to the FP/N611 glycan hole region were primed, although exhibited limited neutralization breadth. Application of cryoEMPEM delineated key residues for on-target and off-target responses that can drive the next round of structure-based vaccine design.

Details

Title
Priming antibody responses to the fusion peptide in rhesus macaques
Author
Cottrell, Christopher A. 1   VIAFID ORCID Logo  ; Pratap, Payal P. 1 ; Cirelli, Kimberly M. 2 ; Carnathan, Diane G. 3 ; Enemuo, Chiamaka A. 4 ; Antanasijevic, Aleksandar 1   VIAFID ORCID Logo  ; Ozorowski, Gabriel 1   VIAFID ORCID Logo  ; Sewall, Leigh M. 1 ; Gao, Hongmei 5   VIAFID ORCID Logo  ; Allen, Joel D. 6   VIAFID ORCID Logo  ; Nogal, Bartek 1 ; Silva, Murillo 7 ; Bhiman, Jinal 8 ; Pauthner, Matthias 8 ; Irvine, Darrell J. 9   VIAFID ORCID Logo  ; Montefiori, David 5 ; Crispin, Max 10   VIAFID ORCID Logo  ; Burton, Dennis R. 8   VIAFID ORCID Logo  ; Silvestri, Guido 3 ; Crotty, Shane 11   VIAFID ORCID Logo  ; Ward, Andrew B. 1   VIAFID ORCID Logo 

 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231) 
 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162) 
 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); Emory University, Division of Microbiology and Immunology, Emory National Primate Research Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Emory University, Division of Microbiology and Immunology, Emory National Primate Research Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Duke University Medical Center Durham, Duke Human Vaccine Institute and Department of Surgery, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216) 
 University of Southampton, School of Biological Sciences, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297) 
 Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); The Scripps Research Institute, Department of Immunology and Microbiology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231) 
 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
10  The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); University of Southampton, School of Biological Sciences, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297) 
11  The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162); San Diego, Division of Infectious Disease and Global Public Health, Department of Medicine, University of California, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
Pages
126
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20590105
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3079574595
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.